Manchester, UK company Biorelate Limited (“Biorelate”) and CCC , today announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly article content in XML format licensed through and delivered by CCC’s RightFind XML platform. With this XML integrated into Biorelate’s Galactic AI™ platform, Biopharma companies can now work with the combined services to automatically curate biomedical data from millions of additional full-text articles, revealing previously unseen biomedical insights.
Biorelate provides biomedical insights and knowledge with its proprietary AI platform, Galactic AI™. Galactic AI’s innovative technology uniquely combines natural language processing (NLP) and machine learning (ML) to create a novel high precision knowledge graph of scientific data curated from literature, patents, clinical trials, and other sources of biomedical text. Galactic AI™ not only allows companies to build a more complete understanding of the current state of research, but also connects datapoints across research to reveal otherwise unobserved insights. This approach allows hidden cause-and-effect relationships between drug targets and diseases to be analysed, empowering analyses around mechanism of action, biomarker discovery and toxicology risks. The relationship with CCC extends these capabilities by providing easier access to full-text scientific literature in XML format.
A pioneer in voluntary collective licensing, CCC helps organizations discover, access, integrate, and share information through licensing, content, software, and professional services. With expertise in copyright and information management, CCC and its subsidiary RightsDirect collaborate with stakeholders to design and deliver innovative information solutions that power decision-making based on many data sources and content assets. RightFind XML from CCC provides customers with access to full-text scholarly articles in XML format across dozens of publishers with consistent licensing grants for this additional use of content.
Biorelate’s CEO and founder, Daniel Jamieson commented: “Today, to successfully bring a drug to market in a cost-effective manner, it is vitally important to understand how a drug works as early in the drug development journey as possible. What we are doing at Biorelate is giving people this understanding by curating and analysing data and knowledge hidden within millions of research articles. We are doing this in a way that no one has ever previously achieved and that is having a direct impact on the speed and success of drug discovery programs. Working with CCC will accelerate this process even more.”
Lauren Tulloch, CCC Vice President & Managing Director, Corporate Solutions said: “We are excited to partner with Biorelate and provide full-text content to augment the content already available in GalacticAI™. Our integration with Biorelate helps us serve our life science customers better, supporting their research and development while at the same time serving the publishers of scholarly content by enabling appropriate licensing of this content, which is so critical in drug development.”